McKesson May Acquire Option Care Health for $5 Billion
Healthcare providers should watch this potential consolidation of infusion services for outpatient care.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Should private equity firms be allowed to acquire large-scale healthcare service providers?
McKesson and private equity firm Clayton Dubilier & Rice are reportedly in talks to acquire Option Care Health in a deal valued at more than $5 billion. The potential acquisition, which includes the assumption of debt, could be finalized as soon as October 6, 2026.
Why it matters
The acquisition would signal a significant expansion in the outpatient infusion market, where companies are increasingly moving high-cost intravenous therapies outside of traditional hospital settings. Operators should monitor how this level of consolidation impacts provider pricing power and supply chain access for specialty medications.
The proposed deal is valued at over $5 billion, a figure that includes the assumption of existing debt. Whether this transaction secures regulatory approval remains unknown.
The players
McKesson
A dominant pharmaceutical wholesaler and healthcare supply chain manager with extensive national distribution networks.
Option Care Health
A national provider of home and alternate-site infusion services for patients requiring intravenous medications.
Clayton Dubilier & Rice
A private equity firm known for executing large-scale corporate carve-outs and leveraged buyouts in the healthcare sector.
The details
Option Care Health specializes in infusion services that allow patients to receive intravenous medications in outpatient settings rather than hospitals. Should the deal proceed, it would combine McKesson's massive pharmaceutical distribution scale with a direct-to-patient care provider. The integration would allow for deeper vertical alignment in the specialty drug supply chain, potentially influencing how outpatient centers procure and deliver infusion treatments.
Timeline
October 5, 2026: Acquisition talks regarding the potential deal were reported.
October 6, 2026: An announcement of the transaction could occur.
Market Landscape
This deal follows the pattern of consolidation in the home-infusion market established by the 2019 merger of Option Care and BioScrip. It reflects a broader strategy by distributors to capture higher-margin service revenue at the point of patient care.
Providers and independent clinics should prepare for potential shifts in specialty drug pricing and regional availability of infusion services. Monitor the outcome of this deal to assess whether it triggers new competitive pressures in the outpatient medication market.
The takeaway
Large-scale acquisitions in the infusion space suggest that vertical integration remains a primary strategy for gaining control over patient care delivery. Operators should audit their current specialty pharmacy supply contracts to identify potential vulnerabilities if major national players continue to consolidate provider networks.
Further reading
For more on shifts in care delivery and supply chain management, explore the latest updates in Healthcare.
Live Poll
Should private equity firms be allowed to acquire large-scale healthcare service providers?
